Navigation Links
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Date:10/10/2007

tion technology can enhance the properties of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It can also be used to modify pharmaceutical agents to preferentially target certain systems within the body. It is a technique in which non-toxic polyethylene glycol (PEG) polymers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs.

Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of the company's PEGylation technology platform and NKTR-102. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) preclinical testing and clinical trials for NKTR-102 are long, expensive and uncertain processes, (ii) because the NKTR- 102 product development programs are in the early phases of clinical development, the risk of failure is high and can occur at any stage of development, (iii) the company ma
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
3. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
4. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... NEW YORK , Aug. 29, 2014 ... EDAP TMS S.A. ("EDAP" or the "Company") (NASDAQ: ... action, filed in United States District Court, Southern District ... under 14-cv-6069, is on behalf of a class consisting ... between February 1, 2013 and July 30, 2014, inclusive ...
(Date:8/29/2014)... WEST JORDAN, Utah , Aug. 29, 2014 /PRNewswire/ ... Imaging Solutions, has acquired Polaris Medical Imaging, a leader ... CT scanners. This strategic acquisition allows BC Technical to ... their capabilities, specifically within MR and CT modalities. ... lower cost service," said Mark Alvarez , president ...
(Date:8/29/2014)... Does your doctor know what you,re smoking?  Chances ... marijuana to the over 112,000 currently registered patients under ... the other roughly 20,300+ active physicians listed with the Colorado ... – even though a poll in February 2014 showed 51% ... tried it. "With marijuana legalization underway, every ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... of the Creighton University School of Medicine presented a ... of Clinical Oncology (ASCO) Annual Symposium, June 5th in ... in Gynecologic Cancer Detected by an In Vitro Assay, ... Drug Response Marker test results taken in the primary ...
... Ill., June 6, 2011 As part of its ... misuse, and diversion of prescription medications, the National Association ... the NABP PMP InterConnect. NABP will now focus on ... and their software vendors to finalize the software interface, ...
Cached Medicine Technology:Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers 2NABP PMP InterConnect Development Complete; PMPs Continue to Sign on to Participate in National System for Tracking Drug Abuse and Diversion 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 According to ... a decision that requires Takeda Pharmaceutical Co. and Eli ... damages for claims that the drugmakers concealed information about ... medication Actos. The case, Allen v. Takeda Pharmaceuticals North ... Court, Western District of Louisiana (Lafayette).* , According to ...
(Date:8/30/2014)... Hands On Mobile Massage and ... complete spa experience combining elegant decor, soothing music, ... important ingredient of all, states Marla Kaplan-Pelle, Director ... will enjoy the get-away feel, without leaving the ... "Step into the spacious, luxurious spa and leave ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The Plastic ... in New Jersey and even in the U.S. to ... takes inches off of patients’ waists with deep-tissue heating. ... in small sections, Vanquish is more inclusive to target ... Patients lay comfortably under panels about one inch away ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... Insomnia causes disturbances in every aspect of ... unknowingly developed insomnia and the steps often used to return ... in to the show at this link: Dr. Carol ... August 30, and will be podcasted at this link ... DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... developments regarding,North Carolina,s organ and tissue donation protocol ... hire Corder Philips to aid in the,campaign to ... include a grant received from the License to ... their online,registry and increase outreach efforts by allowing ...
... Members ... -, ... Education Coalition,s Supporting the Children of the,National Guard and Reserve Institute (GRI) ... Emergency,Assistance Fund. The contribution will help support the needs of more than,8,300 ...
... DEERFIELD, IL, Dec. 11 /PRNewswire-FirstCall/ - Cardiome,Pharma Corp. ... partner,Astellas Pharma US, Inc. ("Astellas") today announced that ... U.S. Food and Drug,Administration (FDA) has recommended that ... hydrochloride, an investigational,new drug for rapid conversion of ...
... feelings, study shows , TUESDAY, Dec. 11 (HealthDay ... of the brain, says a University of California, Los ... of Neurology . , The study included 14 adults ... imaging (fMRI) while they evaluated a series of statements ...
... have identified a genetic variant of the DAB2IP ... aggressive prostate cancer. Research teams from the Translational ... of Medicine, the Karolinska Institute in Stockholm, Sweden, ... jointly. , Researchers suspect that the DAB2IP gene ...
... small islands of genes within the human genome is a ... DNA is junk, some of it is used to help ... in Genome Research, Hopkins researchers have now found that this ... to inherited diseases like Parkinsons or mental disorders, may be ...
Cached Medicine News:Health News:North Carolina Coalition on Donation Selects Corder Philips for Newest Campaign 2Health News:TriWest Contributes $25,000 to Washington National Guard Fund and Sponsors Education for Teachers of Military Children 2Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 2Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 3Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 4Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 5Health News:FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation 6Health News:Personal Convictions May Control Both Behavior and Emotions 2Health News:Study finds gene linked to aggressive prostate cancer 2Health News:Study finds gene linked to aggressive prostate cancer 3Health News:More 'functional' DNA in genome than previously thought 2
... Thru-the-Lens Headlight Video Camera System ... Source. Provides surgeon's eye view ... or edit tapes or digital files ... sharp focus from 8" to 36". ...
... automated system that enables you to perform ... hemostatic disordersincluding D-Dimer, Von Willebrand Antigen and ... rerun testing for greater efficiency in your ... service to help your lab increase uptime ...
... Studies have shown that the best, least ... to warm the OR to 72-75 degrees, eliminating ... operating room, though, can cause the surgical team ... can help keep surgeons cool regardless of OR ...
... Embolic Protection System is designed to provide ... when performing carotid stenting interventions. The ACCUNET ... system that utilizes rapid exchange technology so ... filter during catheter manipulations. It is available ...
Medicine Products: